Table 1.
Baseline characteristics.
| Variable | All patients (N = 754) |
|---|---|
| Age in years, median (IQR) | 67 (60–74) |
| Sex, n (%) | |
| Female | 132 (17.5) |
| Male | 622 (82.5) |
| No cirrhosis, n (%) | 82 (10.9) |
| Etiology of cirrhosis, n (%) | |
| Alcohol | 312 (41.4) |
| Viral | 219 (29.0) |
| Other | 141 (18.7) |
| Child-Pugh stage, n (%) | |
| No cirrhosis | 82 (10.9) |
| A | 393 (52.1) |
| B | 279 (37.0) |
| BCLC stage, n (%) | |
| 0 | 10 (1.3) |
| A | 219 (29.0) |
| B | 388 (51.5) |
| C | 137 (18.2) |
| Portal vein invasion | |
| Yes | 128 (17.0) |
| No | 626 (83.0) |
| Extrahepatic Metastases | |
| Yes | 44 (5.8) |
| No | 710 (94.2) |
| Size of the largest lesion in mm, median (IQR) | 39 (26 – 61) |
| Number of lesions, median (IQR) | 2 (1–3) |
| Albumin level, g/L, median (IQR) | 35 (30–39) |
| Bilirubin level, mg/dl, median (IQR) | 1.2 (0.7–1.8) |
| Platelet count, per nl, median (IQR) | 122 (84–187) |
| AST level, U/L, median (IQR) | 61.0 (42.0–94.5) |
| ALT level, U/L, median (IQR) | 40.0 (27.0–63.0) |
| INR, median (IQR) | 1.2 (1.1–1.3) |
| AFP level, ng/ml, median (IQR) | 24.0 (6.0–359.0) |
| Post-TACE treatment | |
| None | 566 (75.1) |
| Systemic treatment | 149 (19.8) |
| Locoregional treatment (SIRT, External radiation) | 39 (5.2) |
AFP, alpha fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; INR, international normalized ratio; TACE, transarterial chemoembolization.